(INNS)
BEGELOMAB(INND)
BEGELOMAB(INNC)
IMMUNOGLOBULIN G2B-KAPPA, ANTI-[HOMO SAPIENS DPP4 (DIPEPTIDYL-PEPTIDASE 4, DIPEPTIDYLPEPTIDASE IV, ADENOSINE DEAMINASE COMPLEXING PROTEIN 2, ADCP2, TP103, T CELL ACTIVATION ANTIGEN CD26, CD26)], MUS MUSCULUS MONOCLONAL ANTIBODY; GAMMA2B HEAVY CHAIN (1-456) [MUS MUSCULUS VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) - IGHG2B*02 (CH1 (121-217), HINGE (218-239), CH2 (240- 349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-213') [MUS MUSCULUS V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; DIMER (229- 229'':232-232'':235-235'':238-238'')-TETRAKISDISULFIDE: RECOMMENDED INN: LIST 73(WHO)
BEGELOMABUM(INN)